Navigation Links
Frost & Sullivan Lauds IncellDx for Developing a Novel, Non-invasive Method for Cervical Cancer Testing
Date:9/11/2012

MOUNTAIN VIEW, Calif., Sept. 11, 2012 /PRNewswire/ -- Based on its recent analysis of the molecular diagnostics market, Frost & Sullivan recognizes IncellDx with the 2012 North American Frost & Sullivan Award for Product Leadership for its pioneering cervical cancer testing technology, a methodology which holds the promise of decreasing the number of unnecessary, painful, and expensive invasive testing procedures. Numerous clinical studies evaluating the company's HPV OncoTect® technology have demonstrated similar sensitivity but much greater specificity for cervical disease than traditional screening processes. Additionally, the core technology holds great promise as a diagnostic test for breast cancer, doing away with the need for more invasive surgical biopsies.

IncellDx's innovative technology aids in the analysis of intact cells using flow or image cytometry after the target protein, DNA, or RNA biomarkers within the cell are bound by labels.

"The cornerstone of IncellDx's revolutionary approach is its proprietary incellFP reagent, which allows for a one-step fixation/permeabilization," says Frost & Sullivan Global Program Manager Jennifer Brice. "The incellFP reagent fixes and permeabilizes the outer cell and nuclear membranes, permitting in situ probe hybridization without destroying prior antibody labeling of cell surface markers."

In 2011, the U.S. Preventive Services Task Force issued new cervical cancer screening recommendations that discouraged the use of human papillomavirus (HPV) screens in young women, since they are more likely to have HPV infections that clear on their own. These recommendations aimed to reduce the number of false positives thrown up by Pap and HPV tests—an issue well-addressed by IncellDx's HPV OncoTect® methodology. The technology is designed to have similar sensitivity to, but much higher specificity than, current high-risk HPV genotyping technologies.

When HPV infections progress towards cervical cancer they integrate into the patient's host genome which causes HPV E6, E7 mRNA to be over-expressed. Frost & Sullivan's competitive benchmarking reveals that IncellDx's HPV OncoTect® methodology has a unique and powerful approach to the detection and quantification of E6 and E7 mRNA inside each collected cervical cell. 

"Unlike other molecular diagnostic technologies that are limited to detecting high-risk HPV infections off of genomic material extracted from lysed cervical cells, IncellDx's patented technology is able to keep the target cervical cells intact and thereby quantify the actual E6, E7 mRNA overexpression in each and every cell," observes Brice. "Studies have shown that the HPV OncoTect® technology is much more predictive of actionable cervical disease than screening for high-risk HPV."

In the near future Frost & Sullivan expects OncoTect 3DxTM to transform the traditional Pap based cytopathology laboratory. With the addition of image cytometry, 3DxTM adds the morphological analysis routinely done in a Pap test to the molecular analysis from the OncoTect® method. Once commercially available this technology will enable laboratories to retire their microscopes for cervical cancer screening and completely digitize their cytopathology testing.

"With as many as 60 million Pap tests analyzed in the U.S. annually, IncellDx's technology could supplant an entire $2 billion Pap screening industry," observes Brice. "And in countries such as China, where the required infrastructure for widespread Pap screening does not even exist, OncoTect 3DxTM could easily become the primary approach to cervical cancer screening."

Looking forward, IncellDx can leverage its burgeoning relationships with many of the world's largest reference laboratories to ensure continued excellence in strategy and operations.

Each year, Frost & Sullivan presents this award to the company that has demonstrated innovation in product features and functionality, and that provides enhanced quality and higher value to customers. The award recognizes the rapid acceptance such innovation finds in the marketplace.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About IncellDx

IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Predicts Growth for the European Vaccines Market
2. Frost & Sullivan: Where Will Laboratory Budgets be Allocated?
3. Frost & Sullivan Acknowledges the Value Dell Healthcare and Life Sciences Brings to the Enterprise Imaging Informatics Marketplace
4. Varying Technology and Application Trends Pep up the Mature Research Antibodies Market, Finds Frost & Sullivan
5. Brazilian Healthcare Industry Thrives in Favorable Socioeconomic Environment, Finds Frost & Sullivan
6. Frost & Sullivan Lauds U-Systems for Its Unique Technology and Strategic Excellence Paving the Way for Robust Growth
7. Frost & Sullivan Recognizes Terso Solutions, Inc. with 2012 Best Practices Award
8. Frost & Sullivan Lauds MobileHelp for Its Outstanding Products and Performance in the North American Health Technology Market
9. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
10. Increasing Minimal Invasive Surgeries to Boost Adoption of Hybrid Operating Rooms in Europe, Says Frost & Sullivan
11. Frost & Sullivan: Improving Economies in Indonesia and Vietnam Present Strong Growth Potential in Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... GLEN BURNIE, Md. , May 10, 2017 /PRNewswire/ ... and retention solutions for the clinical research industry, is ... website, www.CSSiEnroll.com . The new website features both ... better overall user experience and enhances the company,s already ... in the industry. "After many months ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)...  May is Stroke Awareness Month and Omron Healthcare ... methods to prevent a stroke: monitor and manage your ... and Prevention, undetected and uncontrolled hypertension is a leading ... leader in personal heart health technology, recently evolved its ... and stroke and is advancing a national public education ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health data reveals ... located in the Midwest. With the average cost of healthcare rising and the U.S. ... both the quality and affordability of where they live. An annual 2017 report looked ...
(Date:5/26/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... Peace Agreements being discussed by President Donald Trump and the rest of the world. ... speed up peace talks in the continuous battle between Israel and Palestine. The world’s ...
(Date:5/26/2017)... ... ... Cross”: the personal journey of Bob Massey and his faith in the Lord. “THE ... Massey. Bob Massey is small in stature but big in character. As Johnny ... others is apparent in all of his life decisions. , “I’m in the eightieth ...
(Date:5/24/2017)... N.J. (PRWEB) , ... May 24, 2017 , ... ... Clara Maass Medical Center CEO Mary Ellen, hospital employees, and town officials to ... Belleville. , The facility was developed by Rendina as part of its ongoing ...
(Date:5/24/2017)... NY (PRWEB) , ... May 24, 2017 , ... ... of dental implants in Bayside, NY, who have now spent 10 years as ... the New York University (NYU) College of Dentistry. Through the program, private practitioners ...
Breaking Medicine News(10 mins):